Evidence map›Paper›PMID 39221177›Full record

ArticleJournal of pharmaceutical analysis2021

Retraction notice to "A DNA-based nanocarrier for efficient cancer therapy" [J. Pharm. Anal. 11 (2021) 330-339].

Muhammad Abbas, Mirza Muhammad Faran Ashraf Baig, Yaliang Zhang, Yu-Shun Yang, Songyu Wu, Yiqiao Hu, Zhong-Chang Wang, Hai-Liang Zhu

Abstract readRetraction Notice
In one paragraph

Article in Journal of pharmaceutical analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Muhammad AbbasState Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, 210023, PR China.
Mirza Muhammad Faran Ashraf BaigState Key Laboratory of Analytical Chemistry for Life Sciences, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023, PR China.
Yaliang ZhangState Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, 210023, PR China.
Yu-Shun YangState Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, 210023, PR China.
Songyu WuState Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, 210023, PR China.
Yiqiao HuState Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, 210023, PR China.
Zhong-Chang WangState Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, 210023, PR China.
Hai-Liang ZhuState Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, 210023, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This retracts the article DOI: 10.1016/j.jpha.2020.03.005.].

Identifiers

PMID39221177
PMCPMC11364892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.